DRKS00025271招募中4 期
Evaluation of immunogenicity and reactogenicity of heterologous covid-19 vaccine combination ChAdOx-1S followed by BNT162b2 - Covid vaccine combination AstraZeneca and Biontech
niklinik Regensburg Abteilung für Hygiene und Infektiologie0 个研究点目标入组 154 人开始时间: 2021年5月11日最近更新:
适应症
试验速览
- 阶段
- 4 期
- 状态
- 招募中
- 发起方
- 入组人数
- 154
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- N/a: Single Arm Study
- 盲法
- Open (masking not used)
入排标准
- 年龄范围
- 18 Years 至 60 Years（—）
- 性别
- All
入选标准
- •There had been vaccinated 154 HCW of the university clinics of Regensburg an March 15, 2021 with the Astrazeneca vaccine. Everyone who wants to receive the second dose with the vaccine from Biontech is offered the participation in the study.
排除标准
- •First Covid vaccination not with Astrazeneca. contraindication to vaccination with biontech vaccine
研究者
相似试验
尚未招募
4 期
Mixing of COVID vaccines studyCTRI/2021/08/035648Christian Medical College
进行中（未招募）
不适用
The Study of the Immunogenity and Reactogenity of Trivalent, Purified, Inactivated Influenza Vaccine for Parenteral Administration in Adults, for the 2010-2011 Season, Produced by Cantacuzino National Institute of Research and Development for Microbiology and ImmunologyHealthy adult volunteers (2 age-groups: 18-60 years and >60 years old) are vaccinated in order to achieve protection against influenza virus infection with the vaccine containing the influenza virus strains recommended by WHO for the 2010-2011 season in the Northern Hemispherethe immunogenity and reactogenity of the vaccine are assessedEUCTR2010-023105-35-ROCantacuzino National Institute of Research and Development for Microbiology and Immunology
Enrolling By Invitation
不适用
Follow-up: Immunogenicity according to reactogenicity of Covid-19 vaccinesReactogenicity and immunogenicity of ComirnatyDRKS00026982niversity Medical Center Regensburg76
进行中（未招募）
1 期
The 6-in-1 Vaccine StudyEUCTR2018-003451-38-GBClinical Trials and Research Governance (CTRG)240
已完成
1 期
Investigating of the Immunogenicity and Safety of Lactococcus Lactis Vaccine Related to Human Papillomavirus Type 16IRCT20190504043464N1Iran University of Medical Sciences200